Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3040% above fair value
$9.08+0.17 (+1.91%)
Close on Nov 17, 2026Market cap $41.33MP/E –Yield –
Harvard Bioscience r&d expenses
Research and development expenses are spending on new products and technology.
Harvard Bioscience's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.09M, down 3.3% year over year. For fiscal 2025 it was $8.83M, down 15.2% from the year before. Over ten years it grew 3.2% a year on average. The highest annual figure on record is $12.33M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.83M | -15.2% |
| FY2024 | Dec 31, 2024 | $10.41M | -11.5% |
| FY2023 | Dec 31, 2023 | $11.76M | -4.6% |
| FY2022 | Dec 31, 2022 | $12.33M | +14.2% |
| FY2021 | Dec 31, 2021 | $10.80M | +24.3% |
| FY2020 | Dec 31, 2020 | $8.69M | -18.9% |
| FY2019 | Dec 31, 2019 | $10.72M | -2.5% |
| FY2018 | Dec 31, 2018 | $10.99M | +94.7% |
| FY2017 | Dec 31, 2017 | $5.65M | +4.7% |
| FY2016 | Dec 31, 2016 | $5.39M | -16.0% |
| FY2015 | Dec 31, 2015 | $6.42M | +31.6% |
| FY2014 | Dec 31, 2014 | $4.88M | +17.5% |
| FY2013 | Dec 31, 2013 | $4.15M | -4.4% |
| FY2012 | Dec 31, 2012 | $4.34M | +12.1% |
| FY2011 | Dec 31, 2011 | $3.87M | -17.0% |
| FY2010 | Dec 31, 2010 | $4.67M | +6.2% |
| FY2009 | Dec 31, 2009 | $4.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.45M | +12.1% |
| Q1 FY2026 | Mar 31, 2026 | $2.33M | +0.2% |
| Q4 FY2025 | Dec 31, 2025 | $2.18M | -6.2% |
| Q3 FY2025 | Sep 30, 2025 | $2.13M | -16.9% |
| Q2 FY2025 | Jun 30, 2025 | $2.19M | -16.6% |
| Q1 FY2025 | Mar 31, 2025 | $2.32M | -19.5% |
| Q4 FY2024 | Dec 31, 2024 | $2.33M | -26.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.57M | -7.0% |
| Q2 FY2024 | Jun 30, 2024 | $2.63M | -11.2% |
| Q1 FY2024 | Mar 31, 2024 | $2.89M | -0.4% |
| Q4 FY2023 | Dec 31, 2023 | $3.15M | +10.6% |
| Q3 FY2023 | Sep 30, 2023 | $2.76M | -0.1% |
| Q2 FY2023 | Jun 30, 2023 | $2.96M | -15.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.90M | -10.0% |
| Q4 FY2022 | Dec 31, 2022 | $2.85M | -3.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.76M | +3.9% |
| Q2 FY2022 | Jun 30, 2022 | $3.50M | +29.5% |
| Q1 FY2022 | Mar 31, 2022 | $3.22M | +29.5% |
| Q4 FY2021 | Dec 31, 2021 | $2.95M | +25.6% |
| Q3 FY2021 | Sep 30, 2021 | $2.66M | +36.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.70M | +42.4% |
| Q1 FY2021 | Mar 31, 2021 | $2.49M | -0.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.35M | -11.2% |
| Q3 FY2020 | Sep 30, 2020 | $1.95M | -24.0% |
| Q2 FY2020 | Jun 30, 2020 | $1.90M | -31.5% |
| Q1 FY2020 | Mar 31, 2020 | $2.49M | -9.0% |
| Q4 FY2019 | Dec 31, 2019 | $2.65M | -13.1% |
| Q3 FY2019 | Sep 30, 2019 | $2.56M | -7.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.77M | +0.5% |
| Q1 FY2019 | Mar 31, 2019 | $2.74M | +13.9% |
| Q4 FY2018 | Dec 31, 2018 | $3.05M | +99.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.78M | +80.9% |
| Q2 FY2018 | Jun 30, 2018 | $2.76M | +112.8% |
| Q1 FY2018 | Mar 31, 2018 | $2.40M | +86.9% |
| Q4 FY2017 | Dec 31, 2017 | $1.53M | +32.0% |
| Q3 FY2017 | Sep 30, 2017 | $1.54M | +17.5% |
| Q2 FY2017 | Jun 30, 2017 | $1.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.16M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.31M | – |
See a number that looks wrong?